Safety Data Sheet



1. IDENTIFICATION			
Product Information			
Product name	KENALOG®-10 and 40 mg/ml (triamcine	KENALOG®-10 and 40 mg/ml (triamcinolone acetonide) Injectable Suspension	
Version	1.0, 24.02.2015		
Jurisdiction	This Safety Data Sheet was prepared in accordance with the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) for the United States of America (USA) (CFR 1910.1200), European Union (EU) (EC 1272/2008) and United Nations (UN). The following countries utilize the UN GHS classification process: Mexico, Brazil, China, New Zealand, Canada, Japan, Korea and Australia.		
Active substance	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11.beta.,16.alpha.)-		
Synonyms	Sterile Triamcinolone Acetonide Suspension USP; Kenalog-10 Injection; Kenalog-40 Injection; Albicort; Kenacort		
Intended Uses	This material is a finished drug product for patient use. This material is used to provide relief of inflammatory and pruritic skin conditions.		
Company/Undertaking Ider	ntification		
Address	<u>USA</u> Bristol-Myers Squibb Company P.O. Box 191 New Brunswick, New Jersey 08903 United States of America 1-800-332-2056	<u>Ireland</u> Bristol-Myers Squibb Company Swords Laboratories, Watery Lane Swords, Ireland MG-GBS-MSDS-Request@bms.com 353-1813-9456	
Emergency Phone No.	USA (also Canada, Puerto Rico and the Virgin Island): 1-800-424-9300	Ireland: 353-1813-9456	
	Other Countries: See "Section 16" for cour CHEMTREC.	ntry-specific emergency phone numbers from	

2. HAZARDS IDENTIF	2. HAZARDS IDENTIFICATION		
Classification and L	abelling Common to All Jurisdictions		
Classification	Toxic To Reproduction - Reproductive Toxicity - Category 1A Toxic To Reproduction - Developmental Toxicity - Category 1A Effects On Or Via Lactation		
Symbol			
Signal Word	Danger		
Hazard Statements	May damage fertility (male reproductive toxicity, female reproductive toxicity) . May damage the unborn child (developmental toxicity) . May cause harm to breast-fed children.		
Precautionary	Do not breathe dust.		

Bristol-Myers Squibb Company 00000000782

2. HAZARDS IDENTIF	ICATION
Statements	Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid contact during pregnancy/while nursing. Use personal protective equipment as required.
Classification and L	abelling for Specific Jurisdictions
USA	
Classification	Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 1
Hazard Statements	Causes damage to organs (adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin) through prolonged or repeated exposure.
Precautionary Statements	Wash thoroughly after handling. Do not eat, drink or smoke when using this product.
EU	
Classification	Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 2
Hazard Statements	May cause damage to organs (adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin) through prolonged or repeated exposure.
UN	
Classification	Specific Target Organ Systemic Toxicity (Repeated Exposure) - Category 1
Hazard Statements	Causes damage to organs (adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin) through prolonged or repeated exposure.
Precautionary Statements	Wash thoroughly after handling. Do not eat, drink or smoke when using this product.

3. COMPOSITION/INFORMATION ON INGREDIENTS					
			EU only		
Components	Concentration	CAS No.	EC No./REACH Registration No.	Symbol(s)/ R-phrase(s)	H-code(s)
<i>Hazardous components</i> Triamcinolone Acetonide	1 - 4 %	76-25-5	200-948-7	T: R60, R61, R64, R66	H360F H360D H362 H372
Benzyl Alcohol	<= 1 %	100-51-6	202-859-9	Xn: R20/22	H302 H332

				H335
Other ingredients				
Non-Hazardous Ingredients > 90 %	Not available]		
Other information: Sodium hydroxide and/	or hydrochloric acid are	used for p	H adjustment.	See section 16 for
Symbol, R-phrase and H-code text.				

4. FIRST AID MEASURES	
Eye contact	Rinse immediately with plenty of water for at least 15 minutes. Keep eye wide open while rinsing. If exposed or concerned: Get medical attention/advice.
Skin contact	Take off contaminated clothing and shoes immediately. Wash off immediately with plenty of water for at least 15 minutes. Discard contaminated clothing or wash before re-use. If exposed or concerned: Get medical attention/advice.
Inhalation	Move to fresh air. Oxygen or artificial respiration if needed. If exposed or concerned: Get medical attention/advice.
Ingestion	Do NOT induce vomiting. Never give anything by mouth to an unconscious person. If exposed or concerned: Get medical attention/advice.
Notes to Physician	Medical conditions aggravated include: diabetes, liver disorders, infection, immunodeficiency, hypertension, myasthenia gravis, osteoporosis, peptic ulcer, psychotic disorders, colitis, kidney disorders. This product has been reported to interact with the following medications: diuretic, cyclosporine, immunosuppressants, NSAID (non-steroidal antiinflammatory drugs), drugs metabolized by cytochrome P-450, drugs that cause hyperglycemia, oral hypoglycemic drugs, neuromuscular blocking agents, fluoroquinoline antibiotics, certain vaccines, drugs that inhibit cytochrome P-450. Refer to Section 11.
Medical Surveillance	The need for a pre-placement physical examination and history for employees with potential exposure to this compound is to be evaluated by a physician that is thoroughly knowledgeable about both the toxicity of this compound and the extent of work place exposure. Baseline testing would include: blood glucose test, a complete blood count with differential, a blood test for liver function, a blood test for kidney function. Based on opportunity for exposure and duration of exposure a periodic follow-up examination may be considered. Employees who are pregnant, are breast-feeding, or who are concerned with other reproductive issues should be encouraged to consult with the occupational health physician monitoring worker's health.

5. FIRE-FIGHTING MEASURES		
Flammable Properties	Not available	
Extinguishing Media	Suitable extinguishing media: Dry chemical, Water spray, Foam Unsuitable extinguishing media: Do NOT use water jet.	
Protection of Firefighters	 Specific hazards: Refer to HAZARDS IDENTIFICATION section for a description of hazards for this material. Protective equipment: Use personal protective equipment. In the event of fire, wear self-contained breathing apparatus. Hazardous Combustion Products: carbon oxides (COx), hydrogen halides Further Information: HCl gas can form flammable or explosive mixtures with alcohols or metals. In the event of fire and/or explosion do not breathe fumes. 	
Other information	Decontaminate protective clothing and equipment before reuse.	

6. ACCIDENTAL RELEAS	E MEASURES
Personal precautions	Refer to protective measures listed in sections 7 and 8. Use personal protective equipment. Examples include tightly fitting safety goggles, lab coat and impervious gloves. Wear respiratory protection. Depending on the nature of the spill (quantity and extent of spill) additional protective clothing and equipment such as a self-contained breathing apparatus may be needed.
Environmental precautions	Prevent release to drains and waterways. Prevent release to the environment.
Containment Methods	Contain spillage, and then collect with non-combustible absorbent material, (e.g. sand, earth, diatomaceous earth, vermiculite) and place in container for disposal according to local / national regulations (see section 13).
Cleanup Methods	Contain and collect spillage and place in container for disposal according to local regulations (see Section 13). Clean area with detergent and water after spill pick-up, if appropriate. Handle waste materials, including gloves, protective clothing, contaminated spill cleanup material, etc., as appropriate for chemically and pharmacologically similar materials.

7. HANDLING AND STORAGE		
Handling Precautions	Avoid exposure - obtain special instructions before use. Avoid inhalation of vapour or mist. Keep away from heat and sources of ignition. Prevent release to drains and waterways.	
Container Requirements	Store in sturdy containers appropriate to maintain the integrity of this material for its intended use. Store in spill containment pallet or other device to confine spills.	
Storage Conditions	Store at room temperature. Protect against light. Keep away from heat, sparks and flames. Store locked up.	
Specific use(s)	Refer to Section 1	

8. EXPOSURE CONTRO	OLS / PERSONAL PROTECTIO	ON		
Exposure limit(s)	Company Guideline	ACGIH	Germany OEL	UK MEL
Triamcinolone Acetonide	1 μg/m3 8 hour-TWA			
	(Skin)			
Benzyl Alcohol				
Sodium Hydroxide		2 mg/m3 Ceiling		
Hydrochloric Acid		2 ppm Ceiling	5 ppm MAK 7.6 mg/m3 MAK 2 ppm TWA 3 mg/m3 TWA 4 ppm Peak 6 mg/m3 Peak 2 ppm MAK 3.0 mg/m3 MAK	5 ppm STEL 1 ppm TWA 2 mg/m3 TWA

8. EXPOSURE CONTRO	OLS / PERSONAL PROTECTION
Benzyl Alcohol	Occupational Exposure Limits have been established by: - Czech Republic - Poland - Latvia
Sodium Hydroxide	Occupational Exposure Limits have been established by: - Austria - Belgium - Switzerland - Czech Republic - Denmark - Estonia - Spain - Finland - France - Greece - Hungary - Ireland - Norway - Poland - Portugal - Sweden - Latvia
Hydrochloric Acid	Occupational Exposure Limits have been established by: - Austria - Belgium - Switzerland - Czech Republic - Denmark - Estonia - Spain - Finland - France - Greece - Hungary - Ireland - Italy - The Netherlands - Norway - Poland - Portugal - Sweden - Latvia
Recommended Industrial Hygiene Monitoring Methods	Contact the Bristol-Myers Squibb AIHA accredited Industrial Hygiene Laboratory at (USA) 732-227-6338. General - The health hazard risk of handling this material is dependent on many factors, including physical form, % API in material being handled, duration and frequency of process task, and effectiveness of controls. If it is necessary to handle this compound outside of engineering controls, an exposure risk assessment should be conducted and procedures
	documented by a qualified EHS professional.
	DLS / PERSONAL PROTECTION FOR MATERIAL AS SUPPLIED
	ains an active pharmaceutical ingredient (API) with the guideline limit noted above. To keep the nended guideline, the material as supplied should be controlled during handling to limit total sure to: $25 \ \mu g/m^3$.
Engineering Controls and Ventilation	FOR MANUFACTURING PROCESSES (BULK): Use process enclosures, containment technology, or other engineering controls to keep airborne levels below recommended exposure limit. When handling quantities up to 150 milligrams, a standard laboratory with general laboratory dilution ventilation (e.g. 6-12 air changes per hour) is appropriate. When handling quantities from 150 milligrams to 1 kilogram, work in a standard laboratory using a fume hood; biological safety cabinet(Class II, all types); and, approved vented enclosure. Quantities exceeding 1 kilogram should be handled in a designated laboratory using laminar flow/powder containment booth. When handling solutions with low energy operations (pipette transfers, pouring, low velocity stirring, fraction collection, etc.) use protective shielding to limit the spread of splash or splatter. For manufacturing and pilot plant operations, use direct coupling and closed transfer systems for all bulk transfers. Use dust tight valves as appropriate. HEPA filtration of local exhaust ventilation (LEV) is required. FOR CLINICAL SETTING USE (DRUG PRODUCT): When handling small quantities in a clinical setting, good room ventilation is desirable. Specific engineering controls should not be needed.
Respiratory protection	Use and selection of respiratory protection is based upon engineering controls in use and potential for aerosol generation. When engineering controls are not sufficient control exposure, wear an approved respirator with NIOSH Class 100 or high efficiency particulate (HEPA) filters or cartridges (EN 140/EN 136) when exposures are up to 10 times the exposure control guideline. Wear a loose-fitting (Tyvek or helmet type) HEPA powered-air purifying respirator (PAPR) (EN 12941) when exposures are 10-25 times the exposure control guideline. Wear a full facepiece negative pressure respirator with Class 100 or HEPA filters (EN 136) when exposures are 25-50 times the exposure control guideline. Wear a tight-fitting, full facepiece HEPA PAPR (EN 12942) when exposures are 50-100 times the exposure control guideline. Wear a hood-shroud HEPA PAPR (EN 12941) or full facepiece supplied air respirator (EN 139) operated in a pressure demand or other positive pressure mode when exposures are 100-1000 times the exposure control guideline.

8. EXPOSURE CONT	ROLS / PERSONAL PROTECTION
Eye protection	Safety glasses with side-shields are recommended (EN 166). Face shields or chemical safety goggles (EN 166) may be required if splash potential exists or if corrosive materials are present. Note: Choice of eye protection may be influenced by the type of respirator which is selected.
Hand protection	Impervious nitrile, rubber and latex gloves are recommended (EN 420, EN 374). If material is handled in solution, the solvent should also be considered when selecting protective clothing material. Please note that employees who are allergic to natural rubber latex should use nitrile gloves.
Skin and body protection	Wear a laboratory coat (EN 340) when handling quantities up to 1 kilogram. For quantities over 1 kilogram, wear laboratory coat(EN 340)or coverall of low permeability (EN 1149-1). For manufacturing operations, wear coverall of low permeability (EN 465/1149-1). For manufacturing operations, wear coverall of low permeability.
Hygiene	Wash hands and face before breaks and immediately after handling the product.
Environmental exposure controls	Prevent release to drains and waterways.

9. PHYSICAL AND CHEMICAL PROPE	RTIES	
General Information		
Appearance		
Physical State	liquid	
Color	white to off-white	
Form	suspension	
Odour		
Odour	Not remarkable.	
Odor Threshold	Not available	
pН	5 - 7	
Other information		
Bulk density	Not available	
Evaporation rate	Not available	
Molecular formula	Not applicable	
Hydrolysis/Photolysis	Not available	
Hygroscopicity	Not available	
Molecular Weight	Not applicable	
Log Octanol/Water Partition Coefficient [log Kow]	Not available	
Surface Tension	Not available	
рКа	Not available	
Particle Size	Not available	
Solubility, Water	soluble	
Specific Gravity/ Relative density	1.015	
Viscosity, dynamic	similar to water	
Viscosity, kinematic	Not available	
% Volatile	Not available	

9. PHYSICAL AND CHEMICAL PROPERTIES			
Thermal/Stability properties			
Autoignition temperature	Not available		
Boiling Point	100 °C		
Thermal decomposition	Not available		
Explosive Limits, LEL	Not available		
Explosive limits, UEL	Not available		
Explosiveness	Not available		
Flammability	Not available		
Flash point	Not available		
Melting Point	0 °C		
Oxidizing Potential	Not available		
Vapor Properties			
Vapor Density	(Air =1): If adequate temperatures caused material to volatize, its vapor		
	density would be much greater than 1. (Heavier than air)		
Vapor Pressure	Not available		
Saturated Vapor Concentration	Not available		

10. STABILITY AND REACTIVITY			
Stability			
Chemical Stability	Stable under normal conditions.		
Conditions to avoid	Not available		
Materials to avoid	Not available		
Hazardous decomposition products	Hazardous decomposition products formed under fire conditions.: carbon oxides (COx), hydrogen halides		
Hazardous reactions	Not available		
Sensitivity to static di	ischarge/Dust exp.		
Summary Statements	not applicable		

11. TOXICOLOGICAL INFORMATION				
Routes of Entry	Ingestion, inhalation, Eye contact, Skin contact			
Eye Irritation	<u>Triamcinolone Acetonide</u> Mildly and/or transiently irritating to eyes <u>Benzyl Alcohol</u> Irritating to eyes.			
Skin Irritation	Triamcinolone Acetonide			

11. TOXICOLOGICA	Repeated exposure may cause skin dryness or cracking. skin thinning
	<u>Benzyl Alcohol</u> Mildly irritating to skin
Respiratory Irritation	<u>Triamcinolone Acetonide</u> May cause irritation of respiratory tract. <u>Benzyl Alcohol</u>
	Irritating to respiratory tract.
Sensitization	<u>Triamcinolone Acetonide</u> Not a dermal sensitizer Allergic contact dermatitis is quite rare but has been reported.
	Benzyl Alcohol Several studies were conducted. The results were negative and positive. Only rare mild cutaneous sensitization reactions have been observed in adults.
Acute Toxicity Study	Acute Oral <u>Triamcinolone Acetonide</u> LD50 (mouse): 5,000 mg/kg
	Benzyl Alcohol LD50 (rat): 1,230 mg/kg LD50 (mouse): 1,360 mg/kg LD50 (rabbit): 1,040 mg/kg LD50 (guinea pig): 2,500 mg/kg
	Acute Dermal <u>Benzyl Alcohol</u> LD50 (rabbit): 2,000 mg/kg
	Acute inhalation toxicity Benzyl Alcohol LC50 (rat): 8.8 mg/l/4 H
	Acute toxicity (other routes of administration) <u>Triamcinolone Acetonide</u> LD50 (rat, subcutaneous): 13.1 mg/kg LD50 (mouse, subcutaneous): 132 mg/kg LD50 (mouse, intraperitoneal): 105 mg/kg
Repeated Dose Toxicity	<u>Benzyl Alcohol</u> 16 D - 24 months oral (daily) rat, mouse study (males and females): LOAEL = 200 mg/kg; High dose effects include: irregular respiration, lethargy, abnormal gait, decreased weight gain, mortality. High dose microscopic effects include: kidney, brain, muscle, thymus.

11. TOXICOLOGICAL			
Genetic Toxicity	Triamcinolone Acetonide In vitro Ames reverse-mutation assay negative Forward gene mutation assay negative Mutagenicity Assessment Several studies were conducted. The weight of evidence demonstrates that this material is not genotoxic. Benzyl Alcohol Mutagenicity Assessment The weight of evidence demonstrates that this material is not genotoxic.		
Carcinogenicity	Triamcinolone Acetonide 2 years oral (daily) rat study : Tumor NOAEL = 0.001 mg/kg No treatment-related tumors were observed. 2 years oral (daily) mouse study : Tumor NOAEL = 0.003 mg/kg No treatment-related tumors were observed. 2 years drinking water (daily) rat study : Tumor LOAEL = 0.0048 mg/kg [tumor organs: liver] Carcinogenicity Assessment Not classifiable as to its carcinogenicity to humans. Benzyl Alcohol 2 Years oral (5/week) rat study : Tumor NOAEL = 400 mg/kg (males and females). No treatment-related tumors were observed. 2 Years oral (5/week) mouse study : Tumor NOAEL = 200 mg/kg (males and females). No treatment-related tumors were observed. 2 Years oral (5/week) mouse study : Tumor NOAEL = 200 mg/kg (males and females). No treatment-related tumors were observed. 2 Years oral (5/week) mouse study : Tumor NOAEL = 200 mg/kg (males and females). No treatment-related tumors were observed. Carcinogenicity Assessment This material did not show carcinogenic potential in animal studies.		
Carcinogenicity	ACGIH	IARC	NTP
Triamcinolone Acetonide			
Benzyl Alcohol			
Reproductive Toxicity	<u>Triamcinolone Acetonide</u> Assessment Reproductive Toxicity Several studies were conducted. May impair fertility. Maternal effects include: menstrual irregularities . Paternal effects include: sperm abnormalities See "Human Experience". See also "Developmental Toxicity" for information on reproductive effects.		
Developmental Toxicity	<u>Triamcinolone Acetonide</u> Developmental Toxicity Assessment Several developmental studies were conducted. Birth defects were observed in animal studies Compound may be toxic during early embryonic development. Teratogen This compound and/or its metabolites may be excreted into the milk. May cause harm to breastfed babies.		

11. TOXICOLOGICAL I	NFORMATION
	Benzyl Alcohol Developmental Toxicity Assessment Limited data are available.
Human experience	 Experiences with Human Exposure <u>Triamcinolone Acetonide</u> General effects therapeutic use low exposure - acute effects include: muscle weakness, muscle pain, bone fractures, infection, oedema, headache, difficulty sleeping, vertigo, restlessness, euphoria, mental disturbance, depression, anxiety, mood changes, seizure disorders, nosebleeds, cough, fever, nausea, anaphylaxis, vomiting, anorexia, gastrointestinal disturbance, sore throat, dry mouth, taste disturbance, speech difficulty, congestion, redness and swelling of eyes, vision changes, facial swelling, allergic reactions, skin thinning, acne, redness and swelling of skin, hives, bruising, superficial burning sensation, tingling, increase in blood pressure, Cushing's syndrome, electrolyte disturbance, hyperglycemia, adrenocortical insufficiency, withdrawal symptoms, osteoporosis, bone effects, menstrual irregularities, impaired spermatogenesis, cataracts, glaucoma, nose changes, otitis, peptic ulcer, psychiatric disorders, pancreatitis, changes in white blood cell parameters, alopecia, asthma, growth retardation, skin effects, injection site reactions, cardiac disorders, death.
	<u>Benzyl Alcohol</u> See also symptoms below.
Target Organs	<u>Triamcinolone Acetonide</u> adrenal glands, bone, muscle, gastrointestinal tract, immune system, eyes, nervous system, skin, female reproductive organs, male reproductive organs <u>Benzyl Alcohol</u> central nervous system
Symptoms	Triamcinolone Acetonide See "Human Experience". Benzyl Alcohol nausea, vomiting, diarrhoea, CNS depression, dizziness, headache, vision changes, rash, redness and swelling of skin, vertigo, delirium
Pharmacokinetics/ Toxicokinetics	<u>Triamcinolone Acetonide</u> Absorption: Not available Distribution: Not available Metabolism: Not available Elimination: Half-life = 2 - 3 Hour(s) (Human).

Bristol-Myers Squibb Company 00000000782

11. TOXICOLOGICAL INFORMATION		
Other Toxicity Information	Not available	
Other Information: This SDS may contain toxicological and/or pharmacological information derived from either the specified product or from compounds in the same pharmacological class.		

12. ECOLOGICAL INFORMATION			
Ecotoxicity effects			
Acute Toxicity to Fish			
Benzyl Alcohol			
LC50 (Pimephales prom	elas, 96 H): 460 mg/l.		
LC50 (Lepomis macroch			
Acute Toxicity to Aquatic In			
Triamcinolone Acetonide			
	Water flea), 48 H : > 100 mg/l.		
Benzyl Alcohol			
EC50 (water flea, 48 H)	: 23 mg/l.		
Toxicity to aquatic plants			
Benzyl Alcohol			
EC50 (Anabaena variabi	lis, 3 H): 35 mg/l		
Toxicity to microorganisms			
Benzyl Alcohol			
EC50 (Photobacterium p	hosphoreum, 30 Minute): 71.4 mg/l		
X7 1 114	NT / 111		
Mobility	Not available		
Persistence and degradability			
Biodegradation			
Triamcinolone Acetonide			
biodegradation in t	adation (28 D): 3 %; Not Readily Biodegradable - unlikely to undergo rapid		
Benzyl Alcohol	ine environment		
	D > 0.0% Poolicy biodegradable rapidly biodegrades in the environment		
Ready biodegradation (30 D): > 90 %; Readily biodegradable - rapidly biodegrades in the environment			
Summary Statements			
Chemical Fate			
KENALOG®-10 and 40 mg/ml (triamcinolone acetonide) Injectable Suspension			
Not readily biodegradable			
PBT and vPvB assessment	Not available		
13. DISPOSAL CONSIDERATIONS			
Advice On Disposal And Packaging	Disposal should be in accordance with applicable regional, national and local		
	laws and regulations. Local regulations may be more stringent than regional		
	or national requirements. This information presented only applies to the		
	of national requirements. This information presented only appres to the		

 material as supplied.

 Other information

 Disposal by incineration is recommended.

14. TRANSPORT INFORMATION

This material is not a dangerous good for the purpose of transportation in all modes.

Bristol-Myers Squibb Company 00000000782

15. REGULATORY INI	FORMATION
United States of An	nerica
313 Toxic Release Inventory	No components listed on the SARA 313 inventory.
TSCA Inventory	Not listed. Food, drug and cosmetic products are exempt from TSCA.
EU Directive 1999/4	45/EC
BULK MATERI	<u>IAL</u>
Symbol(s)	T: Toxic
R-phrase(s)	R60: May impair fertility.R61: May cause harm to the unborn child.R64: May cause harm to breastfed babies.
S-phrase(s)	 S23: Do not breathe gas/fumes/vapour/spray. S36/37/39: Wear suitable protective clothing, gloves and eye/face protection. S38: In case of insufficient ventilation, wear suitable respiratory equipment. S45: In case of accident or if you feel unwell, seek medical advice immediately (show label where possible). S53: Avoid exposure - obtain special instructions before use.
DRUG PRODUC	CT
Classification	Medicinal products are exempt from classification and labeling requirements under EU Preparations Directive 1999/45/EC.
Regulatory Authorizations and Restrictions:	Not available

16. OTHER INFORMATION				
Text of Symbol(s), R-phrase(s) and H-code(s) mentioned in Section 3				
H302	Harmful if swallowed.			
H332	Harmful if inhaled.			
H335	May cause respiratory irritation.			
H360D	May damage the unborn child			
H360F	May damage fertility			
H362	May cause harm to breast-fed children.			
H372	Causes damage to organs through prolonged or repeated exposure.			
R20/22	Harmful by inhalation and if swallowed.			
R60	May impair fertility.			
R61	May cause harm to the unborn child.			
R64	May cause harm to breastfed babies.			
R66	Repeated exposure may cause skin dryness or cracking.			
Т	Toxic			
Xn	Harmful			
Recommended Restrictions for Use:				
Not avail	able			
SDS preparation information				

KENALOG®-10 and 40 mg/ml (triamcinolone acetonide) Injectable Suspension

Bristol-Myers Squibb Company 00000000782

Prepared by	Research and Development Environment, Health and Safety 1-732-227-7380		
Prepared on	24.02.2015 DD/MM/YYYY		
	This Safety Dat	a Sheet was reformatted in a	accordance with the Globally Harmonized
	System of Classification and Labeling of Chemicals (GHS) for the United States of		
	America (USA) (CFR 1910.1200), European Union (EU) (EC 1272/2008) and United		
	Nations (UN).		
Other information	· · · · · ·		
HMIS	Health		2*
	Flammability		Not Determined (ND)
	Reactivity		Not Determined (ND)
	Personal protective equipment		See Section 8.
NFPA	Health Fire Reactivity Special	2 ND ND ND	2 ND ND ND

KENALOG®-10 and 40 mg/ml (triamcinolone acetonide) Injectable Suspension

Bristol-Myers Squibb Company 00000000782

Page 14 of 14

Country- Specific Emergency Phone Numbers	CHEMTREC In-Country Dial Numbers	Local # Provided in Country	Toll Free in Country*	Greeting Language
	CHEMTREC South Africa*		0-800-983-611	English
	CHEMTREC Argentina (Buenos	+(54)-1159839431		Latin American
	Aires) CHEMTREC Brazil (Rio De Janeiro)	4/EE) 0100E01440		Spanish
		+(55)-2139581449		Portuguese Latin American
	CHEMTREC Chile (Santiago)	+(56)-25814934		Spanish
	CHEMTREC Colombia *		01800-710-2151	Latin American Spanish
	CHEMTREC Mexico*		01-800-681-9531	Latin American Spanish
	CHEMTREC Peru (Lima)	+(51)-17071295		Latin American Spanish
	CHEMTREC China*	4001-204937		Mandarin
	CHEMTREC Hong Kong (Hong Kong)*		800-968-793	Cantonese
	CHEMTREC India *		000-800-100-7141	Hindi
	CHEMITREC Indonesia*		001-803-017-9114	Indonesian
	CHEMTREC Japan (Tokyo)	+(81)-345209637		Japanese
	CHEMTREC Malaysia *		1-800-815-308	Malay
	CHEMTREC Philippines *		1-800-1-116-1020	Tagalog
	CHEMTREC Singapore*		800-101-2201	Mandarin
	CHEMTREC Singapore	+(65)-31581349		Mandarin
	CHEMTREC South Korea*		00-308-13-2549	Korean
	CHEMTREC Taiwan*		00801-14-8954	Mandarin
	CHEMTREC Thailand *		001-800-13-203- 9987	Thai
	CHEMTREC Vietnam (Ho Chi Minh City)	+(84)-838012436		Vietnamese
	CHEMTREC Australia (Sydney)	+(61)-290372994		English
	CHEMTREC Belgium (Brussels)	+(32)-28083237		French and Flemish
	CHEMTREC Czech Republic (Prague)	+(420)-228880039		Czech
	CHEMTREC France	+(33)-975181407		French
	CHEMTREC Germany *		0800-181-7059	German
	CHEMTREC Hungary (Budapest)	+(36)-18088425		Hungarian
	CHEMTREC Italy *		800-789-767	Italian
	CHEMTREC Italy (Milan)	+(39)-0245557031		Italian
	CHEMTREC Netherlands	+(31)-858880596		Dutch
	CHEMTREC Poland (Warsaw)	+(48)-223988029		Polish
	CHEMTREC Spain*		900-868538	European Spanish
	CHEMTREC Sweden (Stockholm)	+(46)-852503403		Swedish
	CHEMTREC Switzerland (Zurich)	+(41)-435016715		German
	CHEMTREC UK (London)	+(44)-870-8200418		English
	CHEMTREC Bahrain (Bahrain)	+(973)-16199372		Arabic
	CHEMTREC Israel (Tel Aviv)	+(972)-37630639		Hebrew
	*Phone numbers for countries mark		be dialed within the o	
	his SDS is believed to be accurate and represents the best information reasonably			